The effect of acid reduction with a proton pump inhibitor on the pharmacokinetics of lopinavir or ritonavir in HIV-infected patients on lopinavir/ritonavir-based therapy.
Overton
Edgar T
ET
Washington University School of Medicine, 660 S Euclid Ave, Box 8051, St. Louis, MO 63110, USA. toverton@dom.wustl.edu
Tschampa
Jean M
JM
Klebert
Michael
M
Royal
Mike
M
Rodriguez
Mark
M
Spitz
Teresa
T
Kim
GeYoul
G
Mondy
Kristin E
KE
Acosta
Edward P
EP
D000328:Adult; D023241:Antiretroviral Therapy, Highly Active; D004347:Drug Interactions; D005260:Female; D015658:HIV Infections / Q000188:drug therapy*; D017320:HIV Protease Inhibitors / Q000493:pharmacokinetics* / Q000627:therapeutic use; D006801:Humans; D061466:Lopinavir; D008297:Male; D008875:Middle Aged; D009853:Omeprazole / Q000627:therapeutic use*; D054328:Proton Pump Inhibitors / Q000627:therapeutic use*; D011744:Pyrimidinones / Q000493:pharmacokinetics* / Q000627:therapeutic use; D019438:Ritonavir / Q000493:pharmacokinetics* / Q000627:therapeutic use; D055815:Young Adult
D017320:HIV Protease Inhibitors; D054328:Proton Pump Inhibitors; D011744:Pyrimidinones; D061466:Lopinavir; D009853:Omeprazole; D019438:Ritonavir